PI3K/Akt/mTOR signaling pathway in cancer stem cells

被引:58
|
作者
Fath, Mohsen Karami [1 ]
Ebrahimi, Menooa [2 ]
Nourbakhsh, Ehsan [3 ]
Hazara, Ahmad Zia [4 ]
Mirzaei, Ali [5 ]
Shafieyari, Saba [6 ]
Salehi, Azadeh [7 ]
Hoseinzadeh, Mahsa [8 ]
Payandeh, Zahra [9 ]
Barati, Ghasem [10 ]
机构
[1] Kharazmi Univ, Fac Biol Sci, Dept Cellular & Mol Biol, Tehran, Iran
[2] Qazvin Univ Med Sci, Shahid Babai Fac Med, Qazvin, Iran
[3] Shahid Beheshti Univ Med Sci, Fac Med, Tehran, Iran
[4] Shahid Sadoughi Univ Med Sci, Dept Immunol, Yazd, Iran
[5] Shiraz Univ Med Sci, Fac Nursing & Midwifery, Shiraz, Iran
[6] Hamadan Univ Med Sci, Fac Med, Hamadan, Iran
[7] Islamic Azad Univ, Tehran Branch, Fac Pharm, Tehran, Iran
[8] Islamic Azad Univ Jahrom, Dept Biol Sci & Technol, Jahrom, Fars, Iran
[9] Karolinska Inst, Dept Med Biochem & Biophys, Div Med Inflammat Res, Solna, Sweden
[10] Stem Cell Technol Res Ctr, Tehran, Iran
关键词
Cancer stem cell; PI3K; Akt; mTOR pathway; Targeted cancer therapy; Pathogenesis; TUMOR-INITIATING CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; ROTTLERIN INDUCES AUTOPHAGY; ACUTE MYELOID-LEUKEMIA; COLORECTAL-CANCER; DOWN-REGULATION; MTOR; RAPAMYCIN; CD44; ACTIVATION;
D O I
10.1016/j.prp.2022.154010
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Cancer stem cells (CSCs) as a small subpopulation in tumor bulk are believed to initiate tumor formation and are responsible for the resistance to cancer therapy. The proliferation and differentiation of CSCs result in heterogeneity in a tumor which increases the chance of tumor survival and invasion. Many signaling pathways are abnormally activated or repressed in CSCs. Understanding these pathways and the metabolisms in CSCs may help targeted therapy in drug-resistant tumors. The PI3K/Akt/mTOR pathway is one of the major signaling pathways in CSCs involved in the maintenance of stemness, proliferation, differentiation, epithelial to mesenchymal transition (EMT), migration, and autophagy. Thus, suppressing the PI3K/Akt/mTOR pathway with inhibitors might be a promising strategy for targeted cancer therapy. Although the pathway is well-recognized and reviewed in tumor bulks, the functions in CSCs have not been well focused. Here, we reviewed the PI3K/Akt/ mTOR signaling pathway and its functions in CSCs and addressed the potential therapeutic applications in drugresistant tumors.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] The PI3K/Akt/mTOR signaling pathway
    Dennis, P. A.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 : 19 - 19
  • [2] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    [J]. Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [3] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    [J]. CANCERS, 2021, 13 (14)
  • [4] RAS Signaling in the PI3K/AKT/MTOR Pathway
    Nussinov, Ruth
    Zhang, Mingzhen
    Jang, Hyunbum
    [J]. BIOPHYSICAL JOURNAL, 2020, 118 (03) : 51A - 51A
  • [5] PI3K/Akt/mTOR signaling pathway in cancer stem cells: from basic research to clinical application
    Xia, Pu
    Xu, Xiao-Yan
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (05): : 1602 - 1609
  • [6] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    [J]. FRONTIERS IN ONCOLOGY, 2014, 4
  • [7] Hypoxia leads to deregulation of PI3K/AKT/mTOR signaling in prostate cancer stem cells
    Marhold, Maximilian
    Tomasich, Erwin
    Pernicova, Zuzana
    Fedr, Radek
    Soucek, Karel
    Spittler, Andreas
    Krainer, Michael
    Horak, Peter
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [8] PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer
    Li, HaiXia
    Zeng, JianFang
    Shen, Keng
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2014, 290 (06) : 1067 - 1078
  • [9] PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
    Leiphrakpam, Premila D.
    Are, Chandrakanth
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [10] The PI3K/AKT/mTOR signaling pathway: Implications in the treatment of breast cancer
    Andreopoulou E.
    [J]. Current Breast Cancer Reports, 2011, 3 (1) : 63 - 74